Disopyramide Phosphate
The phosphate salt form of disopyramide, used in oral and injectable preparations for the treatment of ventricular and supraventricular arrhythmias. Like the parent compound, it blocks cardiac sodium channels and has prominent anticholinergic side effects. Therapeutic drug monitoring is sometimes used to optimize dosing.
Peso Molecular
437,5000 g/mol
TPSA
137,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C.O=P(O)(O)O
InChI
InChI=1S/C21H29N3O.H3O4P/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;1-5(2,3)4/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);(H3,1,2,3,4)
Molecular Formula
C21H32N3O5P
HBD / HBA
4 / 7
Ligações Rotacionáveis
8
Átomos Pesados
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
The phosphate salt form of disopyramide, used in oral and injectable preparations for the treatment of ventricular and supraventricular arrhythmias. Like the parent compound, it blocks cardiac sodium channels and has prominent anticholinergic side effects. Therapeutic drug monitoring is sometimes used to optimize dosing.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Disopyramide Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201020. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 30928. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="disopyramide-phosphate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/disopyramide-phosphate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/disopyramide-phosphate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/disopyramide-phosphate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="disopyramide-phosphate"></drugfyi-drug>